ROIV:NSD-Roivant Sciences Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 10.69

Change

-0.11 (-1.02)%

Market Cap

USD 8.01B

Volume

0.02B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.13 (-0.24%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

+7.30 (+0.69%)

USD 115.08B
MRNA Moderna Inc

+0.60 (+0.44%)

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

+17.25 (+7.74%)

USD 28.20B
ARGX argenx NV ADR

+10.96 (+2.49%)

USD 26.78B
BNTX BioNTech SE

-2.23 (-2.57%)

USD 20.40B
BGNE BeiGene Ltd

-8.16 (-5.13%)

USD 17.50B
GMAB Genmab AS

-0.04 (-0.15%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.17 (-0.20%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.21 (-0.77%)

USD 15.90B

ETFs Containing ROIV

TYNE 4.21 % 0.00 %

N/A

N/A
FHH:CA First Trust AlphaDEX US H.. 2.14 % 0.77 %

N/A

CAD 9.71M
FHH-F:CA First Trust AlphaDEX U.S... 2.14 % 0.00 %

-0.16 (0%)

CAD 0.01B
DSPC 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.81% 58% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.81% 58% F 45% F
Trailing 12 Months  
Capital Gain 9.08% 73% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.08% 73% C 64% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 41.57% 84% B 89% A-
Dividend Return 41.57% 84% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.59% 41% F 24% F
Risk Adjusted Return 60.60% 97% N/A 85% B
Market Capitalization 8.01B 98% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.